# IRulya Therapeutics Inc.: filings

IRLA · Nasdaq · CIK 1662774 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/irla.md) · [Financials](/companies/irla/financials.md) · [Filings](/companies/irla/filings.md) · [Insiders](/companies/irla/insiders.md)

## Reports and events: 127 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 161, 8-K 80, 3 32, 10-Q 23, SC 13G/A 20, S-8 10, SC 13G 10, SCHEDULE 13G 10, DEFA14A 9, CORRESP 8, DEF 14A 8, 10-K 7, 424B5 6, 4/A 6, D 6, EFFECT 6, SCHEDULE 13G/A 6, PRE 14A 5, UPLOAD 5, 8-K/A 4, ARS 4, S-3 3, 144 2, 8-A12B 2, S-1 2, S-1/A 2, 3/A 1, 424B3 1, 424B4 1, 5 1, CERT 1, DRS 1, NT 10-K 1, POS AM 1, POSASR 1, POS EX 1, S-3/A 1, S-3ASR 1, SC 13D 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-19 | 12:49 ET | [8-K](/filings/0001193125-26-424731.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-424731 |
| 2026-10-09 | 11:59 ET | [8-K](/filings/0001193125-26-418538.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-418538 |
| 2026-10-06 | 20:57 ET | [8-K](/filings/0001193125-26-415730.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-415730 |
| 2026-10-02 | 11:30 ET | [8-K](/filings/0001193125-26-411260.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-411260 |
| 2026-09-14 | 20:30 ET | [8-K](/filings/0001193125-26-390652.md) | 2.01 Completion of an acquisition or disposition; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-390652 |
| 2026-09-04 | 12:30 ET | [8-K](/filings/0001193125-26-382838.md) | 3.01 Delisting notice | 0001193125-26-382838 |
| 2026-08-27 | 20:30 ET | [8-K](/filings/0001193125-26-371389.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-371389 |
| 2026-08-25 | 12:30 ET | [DEF 14A](/filings/0001193125-26-364220.md) | Proxy statement, period 2026-10-06 | 0001193125-26-364220 |
| 2026-08-17 | 10:01 ET | [8-K](/filings/0001193125-26-353141.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-353141 |
| 2026-08-14 | 20:05 ET | [10-Q](/filings/0001193125-26-352201.md) | Quarterly report, period 2026-06-30 | 0001193125-26-352201 |
| 2026-08-14 | 12:21 ET | [8-K](/filings/0001193125-26-350568.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-350568 |
| 2026-07-31 | 20:50 ET | [8-K](/filings/0001193125-26-328784.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-328784 |
| 2026-07-30 | 10:02 ET | [8-K/A](/filings/0001193125-26-324786.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-324786 |
| 2026-06-26 | 20:31 ET | [8-K/A](/filings/0001193125-26-285572.md) | 3.03 Change to security holders’ rights | 0001193125-26-285572 |
| 2026-06-26 | 13:18 ET | [8-K](/filings/0001193125-26-284089.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-284089 |
| 2026-06-11 | 21:06 ET | [8-K](/filings/0001193125-26-267862.md) | 5.07 Shareholder vote results | 0001193125-26-267862 |
| 2026-05-21 | 21:06 ET | [8-K](/filings/0001193125-26-234858.md) | 8.01 Other events | 0001193125-26-234858 |
| 2026-05-18 | 20:20 ET | [8-K/A](/filings/0001193125-26-228956.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-228956 |
| 2026-05-18 | 13:33 ET | [8-K](/filings/0001193125-26-228133.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-228133 |
| 2026-05-11 | 21:09 ET | [10-Q](/filings/0001193125-26-217098.md) | Quarterly report, period 2026-03-31 | 0001193125-26-217098 |
| 2026-04-28 | 20:30 ET | [8-K](/filings/0001193125-26-187243.md) | 8.01 Other events | 0001193125-26-187243 |
| 2026-04-27 | 20:39 ET | [DEF 14A](/filings/0001193125-26-182255.md) | Proxy statement, period 2026-06-11 | 0001193125-26-182255 |
| 2026-04-22 | 20:30 ET | [8-K](/filings/0001193125-26-170572.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-170572 |
| 2026-04-10 | 20:35 ET | [10-K](/filings/0001193125-26-151364.md) | Annual report, period 2025-12-31 | 0001193125-26-151364 |
| 2026-04-09 | 13:23 ET | [8-K](/filings/0001193125-26-149021.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-149021 |
| 2026-03-30 | 12:35 ET | [8-K](/filings/0001193125-26-130489.md) | 1.02 Termination of a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-130489 |
| 2026-03-20 | 20:45 ET | [8-K](/filings/0001193125-26-117794.md) | 3.01 Delisting notice | 0001193125-26-117794 |
| 2026-02-12 | 11:06 ET | [8-K](/filings/0001193125-26-047544.md) | 2.02 Results of operations; 8.01 Other events | 0001193125-26-047544 |
| 2026-02-02 | 21:30 ET | [8-K](/filings/0001193125-26-033758.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-033758 |
| 2026-01-29 | 21:40 ET | [8-K](/filings/0001193125-26-029524.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-029524 |
| 2025-11-12 | 21:05 ET | [10-Q](/filings/0001193125-25-277529.md) | Quarterly report, period 2025-09-30 | 0001193125-25-277529 |
| 2025-11-12 | 21:05 ET | [8-K](/filings/0001193125-25-277523.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-277523 |
| 2025-10-17 | 20:11 ET | [8-K](/filings/0001193125-25-242514.md) | 7.01 Regulation FD disclosure | 0001193125-25-242514 |
| 2025-09-26 | 20:45 ET | [8-K](/filings/0001193125-25-220722.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001193125-25-220722 |
| 2025-08-11 | 20:06 ET | [10-Q](/filings/0000950170-25-106535.md) | Quarterly report, period 2025-06-30 | 0000950170-25-106535 |
| 2025-08-11 | 20:05 ET | [8-K](/filings/0000950170-25-106536.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-106536 |
| 2025-07-16 | 20:30 ET | [8-K](/filings/0001193125-25-159886.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-159886 |
| 2025-06-13 | 21:25 ET | [8-K](/filings/0001193125-25-140873.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-25-140873 |
| 2025-06-05 | 20:12 ET | [8-K](/filings/0001662774-25-000034.md) | 5.07 Shareholder vote results | 0001662774-25-000034 |
| 2025-05-13 | 12:40 ET | [10-Q](/filings/0001662774-25-000032.md) | Quarterly report, period 2025-03-31 | 0001662774-25-000032 |
| 2025-05-13 | 12:01 ET | [8-K](/filings/0001662774-25-000031.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001662774-25-000031 |
| 2025-04-23 | 20:00 ET | [DEF 14A](/filings/0001662774-25-000025.md) | Proxy statement, period 2025-06-04 | 0001662774-25-000025 |
| 2025-03-24 | 20:07 ET | [10-K](/filings/0001662774-25-000012.md) | Annual report, period 2024-12-31 | 0001662774-25-000012 |
| 2025-03-24 | 20:06 ET | [8-K](/filings/0001662774-25-000011.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001662774-25-000011 |
| 2024-11-14 | 11:55 ET | [8-K](/filings/0001662774-24-000013.md) | 8.01 Other events | 0001662774-24-000013 |
| 2024-11-13 | 02:17 ET | [SC 13D](/filings/0001193125-24-257646.md) | Ownership report, active investor | 0001193125-24-257646 |
| 2024-11-13 | 22:09 ET | [10-Q](/filings/0001662774-24-000011.md) | Quarterly report, period 2024-09-30 | 0001662774-24-000011 |
| 2024-11-13 | 21:15 ET | [8-K](/filings/0001662774-24-000010.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001662774-24-000010 |
| 2024-08-13 | 20:11 ET | [10-Q](/filings/0001662774-24-000005.md) | Quarterly report, period 2024-06-30 | 0001662774-24-000005 |
| 2024-08-13 | 20:10 ET | [8-K](/filings/0001662774-24-000004.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001662774-24-000004 |

Page 1 of 3. [Older](/companies/irla/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.